Medical - Devices
Compare Stocks
5 / 10Stock Comparison
LNSR vs ISRG vs SYK vs NVCR vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
LNSR vs ISRG vs SYK vs NVCR vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $63M | $161.07B | $112.69B | $1.92B | $99.94B |
| Revenue (TTM) | $58M | $10.58B | $25.12B | $674M | $35.48B |
| Net Income (TTM) | $-34M | $2.98B | $3.25B | $-173M | $4.61B |
| Gross Margin | 46.0% | 66.3% | 63.5% | 75.2% | 61.9% |
| Operating Margin | -42.1% | 30.5% | 22.4% | -27.2% | 17.9% |
| Forward P/E | 1341.0x | 43.8x | 19.6x | — | 14.1x |
| Total Debt | $3M | $303M | $14.86B | $290M | $28.52B |
| Cash & Equiv. | $13M | $3.37B | $4.01B | $103M | $2.22B |
LNSR vs ISRG vs SYK vs NVCR vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| LENSAR, Inc. (LNSR) | 100 | 53.6 | -46.4% |
| Intuitive Surgical,… (ISRG) | 100 | 203.9 | +103.9% |
| Stryker Corporation (SYK) | 100 | 145.7 | +45.7% |
| NovoCure Limited (NVCR) | 100 | 13.8 | -86.2% |
| Medtronic plc (MDT) | 100 | 77.5 | -22.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LNSR vs ISRG vs SYK vs NVCR vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LNSR lags the leaders in this set but could rank higher in a more targeted comparison.
ISRG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs SYK's 187.1%
- 20.5% revenue growth vs MDT's 3.6%
- 28.2% margin vs LNSR's -58.7%
SYK is the clearest fit if your priority is valuation efficiency.
- PEG 1.32 vs MDT's 36.00
NVCR ranks third and is worth considering specifically for momentum.
- +1.1% vs LNSR's -62.2%
MDT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Lower volatility, beta 0.47, Low D/E 59.1%, current ratio 1.85x
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs MDT's 3.6% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs LNSR's -58.7% | |
| Stability / Safety | Beta 0.47 vs NVCR's 2.20, lower leverage | |
| Dividends | 3.6% yield, 36-year raise streak, vs SYK's 1.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +1.1% vs LNSR's -62.2% | |
| Efficiency (ROA) | 175.8% ROA vs LNSR's -48.1% |
LNSR vs ISRG vs SYK vs NVCR vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
LNSR vs ISRG vs SYK vs NVCR vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 2 of 6 categories
MDT leads 2 • LNSR leads 0 • SYK leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 607.2x LNSR's $58M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to LNSR's -58.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $58M | $10.6B | $25.1B | $674M | $35.5B |
| EBITDAEarnings before interest/tax | -$20M | $3.8B | $6.3B | -$165M | $9.4B |
| Net IncomeAfter-tax profit | -$34M | $3.0B | $3.2B | -$173M | $4.6B |
| Free Cash FlowCash after capex | -$15M | $2.8B | $4.3B | -$48M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +46.0% | +66.3% | +63.5% | +75.2% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -42.1% | +30.5% | +22.4% | -27.2% | +17.9% |
| Net MarginNet income ÷ Revenue | -58.7% | +28.2% | +12.9% | -25.7% | +13.0% |
| FCF MarginFCF ÷ Revenue | -25.5% | +26.8% | +17.1% | -7.1% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -4.2% | +23.0% | +11.4% | +12.3% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +92.5% | +18.8% | +56.0% | -100.0% | -11.9% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $63M | $161.1B | $112.7B | $1.9B | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $53M | $158.0B | $123.5B | $2.1B | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.82x | 57.62x | 35.03x | -13.80x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | 1341.03x | 43.84x | 19.62x | — | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.65x | 2.36x | — | 36.00x |
| EV / EBITDAEnterprise value multiple | — | 43.62x | 20.31x | — | 14.32x |
| Price / SalesMarket cap ÷ Revenue | 1.08x | 16.00x | 4.49x | 2.92x | 2.98x |
| Price / BookPrice ÷ Book value/share | — | 9.17x | 5.02x | 5.51x | 2.08x |
| Price / FCFMarket cap ÷ FCF | — | 64.67x | 26.31x | — | 19.28x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs LNSR's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +16.9% | +15.0% | -50.8% | +9.4% |
| ROA (TTM)Return on assets | -48.1% | +14.8% | +6.9% | -16.5% | +175.8% |
| ROICReturn on invested capital | — | +15.0% | +11.4% | -16.4% | +6.0% |
| ROCEReturn on capital employed | -59.8% | +16.5% | +13.0% | -28.9% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.02x | 0.66x | 0.85x | 0.59x |
| Net DebtTotal debt minus cash | -$10M | -$3.1B | $10.8B | $187M | $26.3B |
| Cash & Equiv.Liquid assets | $13M | $3.4B | $4.0B | $103M | $2.2B |
| Total DebtShort + long-term debt | $3M | $303M | $14.9B | $290M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | — | — | 6.72x | -96.80x | 9.08x |
Total Returns (Dividends Reinvested)
Evenly matched — LNSR and ISRG and NVCR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, NVCR leads with a +1.1% total return vs LNSR's -62.2%. The 3-year compound annual growth rate (CAGR) favors LNSR at 24.2% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -55.0% | -19.3% | -15.2% | +28.3% | -18.1% |
| 1-Year ReturnPast 12 months | -62.2% | -15.4% | -22.5% | +1.1% | -2.8% |
| 3-Year ReturnCumulative with dividends | +91.6% | +49.6% | +5.5% | -75.7% | -4.2% |
| 5-Year ReturnCumulative with dividends | -26.8% | +58.7% | +21.5% | -91.3% | -27.7% |
| 10-Year ReturnCumulative with dividends | -41.9% | +554.2% | +187.1% | +30.3% | +26.5% |
| CAGR (3Y)Annualised 3-year return | +24.2% | +14.4% | +1.8% | -37.6% | -1.4% |
Risk & Volatility
Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs LNSR's 36.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.52x | 1.02x | 0.55x | 2.20x | 0.47x |
| 52-Week HighHighest price in past year | $14.31 | $603.88 | $404.87 | $20.06 | $106.33 |
| 52-Week LowLowest price in past year | $5.06 | $427.84 | $289.91 | $9.82 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +36.5% | +75.1% | +72.7% | +83.9% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 38.1 | 42.4 | 24.3 | 69.8 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 130K | 1.8M | 2.1M | 1.5M | 7.8M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: LNSR as "Buy", ISRG as "Buy", SYK as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 37.2% for SYK (target: $404). For income investors, MDT offers the higher dividend yield at 3.57% vs SYK's 1.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $622.60 | $403.69 | $33.50 | $109.50 |
| # AnalystsCovering analysts | 3 | 55 | 50 | 15 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.1% | — | +3.6% |
| Dividend StreakConsecutive years of raises | 1 | — | 34 | — | 36 |
| Dividend / ShareAnnual DPS | — | — | $3.36 | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% | 0.0% | 0.0% | +3.2% |
ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.
LNSR vs ISRG vs SYK vs NVCR vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LNSR or ISRG or SYK or NVCR or MDT a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate LENSAR, Inc. (LNSR) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LNSR or ISRG or SYK or NVCR or MDT?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — LNSR or ISRG or SYK or NVCR or MDT?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus LNSR's -41. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LNSR or ISRG or SYK or NVCR or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — LNSR or ISRG or SYK or NVCR or MDT?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -5. 1% for LENSAR, Inc.. Over a 3-year CAGR, LNSR leads at 18. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LNSR or ISRG or SYK or NVCR or MDT?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -58. 7% for LENSAR, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -42. 1% for LNSR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LNSR or ISRG or SYK or NVCR or MDT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 1341. 0x for LENSAR, Inc. — 1326. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — LNSR or ISRG or SYK or NVCR or MDT?
In this comparison, MDT (3.
6% yield), SYK (1. 1% yield) pay a dividend. LNSR, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is LNSR or ISRG or SYK or NVCR or MDT better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LNSR and ISRG and SYK and NVCR and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LNSR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. SYK, MDT pay a dividend while LNSR, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.